<DOC>
	<DOC>NCT00404885</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis</brief_summary>
	<brief_title>A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis, Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<criteria>Documented history of noninfectious anterior, anterior and intermediate or panuveitis Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated. Grade of 2+ or higher for anterior chamber cells at time of enrollment Considered by the investigator to require corticosteroidsparing therapy. Subjects not planning to undergo elective ocular surgery during the study Uveitis of infectious etiology Presence of an ocular toxoplasmosis scar An immune suppression regimen that includes an alkylating agent within the previous 90 days</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>uveitis</keyword>
	<keyword>calcineurin</keyword>
	<keyword>inflammation</keyword>
</DOC>